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Summary
Background Pachyonychia congenita (PC) is a rare autosomal dominant keratinizing
disorder characterized by severe, painful, palmoplantar keratoderma and nail dys-
trophy, often accompanied by oral leucokeratosis, cysts and follicular keratosis. It
is caused by mutations in one of five keratin genes: KRT6A, KRT6B, KRT6C, KRT16
or KRT17.
Objectives To identify mutations in 84 new families with a clinical diagnosis of
PC, recruited by the International Pachyonychia Congenita Research Registry dur-
ing the last few years.
Methods Genomic DNA isolated from saliva or peripheral blood leucocytes was
amplified using primers specific for the PC-associated keratin genes and polymer-
ase chain reaction products were directly sequenced.
Results Mutations were identified in 84 families in the PC-associated keratin genes,
comprising 46 distinct keratin mutations. Fourteen were previously unreported
mutations, bringing the total number of different keratin mutations associated
with PC to 105.
Conclusions By identifying mutations in KRT6A, KRT6B, KRT6C, KRT16 or KRT17, this
study has confirmed, at the molecular level, the clinical diagnosis of PC in these
families.
What’s already known about this topic?
• Pachyonychia congenita (PC) is caused by autosomal dominant mutations in KRT6A,
KRT6B, KRT6C, KRT16 or KRT17.
• Plantar pain is the main symptom.
• Palmoplantar keratoderma and nail dystrophy are the predominant characteristics,
often accompanied by oral leucokeratosis, cysts and follicular keratosis.
What does this study add?
• This study identifies PC-associated keratin mutations in 84 new families with PC
recruited by the International Pachyonychia Congenita Research Registry.
• Fourteen of the 46 distinct keratin mutations were previously unreported.
• This study expands the large well-phenotyped and genotyped case series of patients
with PC, which is an invaluable resource for the development of mutation-specific
and/or gene-specific therapies and for future clinical trials.
© 2014 The Authors. British Journal of Dermatology
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Pachyonychia congenita (PC, OMIM #167200 and #167210)
is a rare autosomal dominant disorder of keratinization, with
hallmark signs of palmoplantar keratoderma (PPK) and nail
dystrophy (Fig. 1). The main symptom is plantar pain. Addi-
tional characteristics include oral leucokeratosis; cysts of
various types, including epidermal inclusion cysts and pilo-
sebaceous cysts; follicular keratoses; hoarseness; hyperhidrosis;
and natal teeth. The severity and clinical features can vary, as
shown in Figure 1. While clinical case reports of PC date back
to 1906,1 and possibly earlier, the understanding behind the
K6a p.Glu472Lys K6b p.Glu472Lys
K6a p.Asn172del K16 p.Leu132Pro
K17 p.Asn92Ser K17 p.Met88Lys
K17 p.Met88Lys
K16 p.Leu132Pro
K17 p.Asn92Ser
K16 p.Ser130del
K6a p.Ile178Asn
K6a p.Asn172del
Fig 1. Clinical features of pachyonychia congenita (PC). Palmoplantar keratoderma, nail dystrophy, oral leukokeratosis and cysts in patients with
PC with identified mutations.
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genetic basis of PC was not elucidated until 1994,2 following
discoveries resulting in epidermolysis bullosa simplex (EBS)
being the first keratin disorder for which the molecular basis
was identified.3–5 Mutations in one of five keratin genes –
KRT6A, KRT6B, KRT6C, KRT16 or KRT17 – are now known to
cause PC.6–9 Formerly classified as PC-1 (caused by mutations
in KRT6A or KRT16) and PC-2 (due to mutations in KRT6B or
KRT17), PC nomenclature has recently been revised based on
the molecular genetic data; for example, those with mutations
in KRT6A are named PC-K6a and those with KRT16 mutations
are PC-K16.10
Keratins comprise the type I and type II groups of the inter-
mediate filament subgroup of cytoskeletal proteins. The 54
known functional keratin genes are divided into epithelial and
hair keratins.11,12 Keratin proteins, albeit very diverse in func-
tion, all share a similar protein structure consisting of an a-heli-
cal central rod domain comprising four domains (1A, 1B, 2A,
2B) connected by nonhelical regions (L1, L12, L2).13 The
majority of mutations causing PC are at the start and end of the
a-helical rod domain (within 1A and 2B) within the helix
boundary motif domains that show evolutionary conservation
throughout all intermediate filaments. These motif regions are
thought to play a vital role in the interaction of filaments during
cytoskeleton construction in forming end–end overlap inter-
actions during filament assembly.14
More than 20 keratin genes are now known to cause
directly or predispose to fragility syndromes (www.interfil.
org), emphasizing the importance of keratins in skin and epi-
thelial appendages. Keratin diseases are almost always inherited
in an autosomal dominant manner where mutations act in a
dominant negative way, disrupting the ability of keratin fila-
ments to form a strong cytoskeleton, leaving the skin in a
fragile, unprotected condition unable to withstand trauma.
The mutational spectrum covers all types (missense mutations,
small deletion/insertion mutations, splice-site mutations and
nonsense mutations), and the disease produced is confined
strictly to the epithelial site where the mutant keratin protein
is normally expressed; for example, keratin K6a is expressed
in palmoplantar epidermis, nail epithelia and mucosal tissues
– the tissues affected in PC.
The International Pachyonychia Congenita Research Registry
(IPCRR) has, to date, collected clinical and molecular data from
more than 500 patients with PC and their families (~270 fami-
lies) worldwide. Here, we report molecular analysis of 84 fami-
lies registered within the last few years of this expanding case
collection with a clinical diagnosis of PC. Mutations were identi-
fied in KRT6A, KRT6B, KRT6C, KRT16 or KRT17. Forty-six distinct
keratin mutations were found, 14 of which were previously
unreported mutations, bringing the total number of different
keratin mutations associated with PC to 105.
Materials and methods
Genomic DNA was extracted from saliva collected in an
Oragene DNA sample collection kit (DNA Genotek, Kanata,
ON, Canada) and extracted according to the manufacturer’s
protocol or from peripheral blood leucocytes using standard
procedures. Samples were obtained by the IPCRR with
informed consent and ethical approval from Western Institu-
tional Review Board (IRB), which complies with all principles
of the Declaration of Helsinki (Western IRB study no.
20040468).
Mutation detection
The coding regions of KRT6A, KRT6, KRT6C, KRT16 and KRT17
were amplified using primers specific to the respective func-
tional genes and to avoid amplification of K16/K17 pseudo-
genes. All primers were checked for single nucleotide polymor-
phisms using Diagnostic SNPCheck (www.ngrl.org.uk/
Manchester), and some have been modified since our previous
publications to increase specificity (Table S1).9,15,16 For ampli-
fication of larger fragments, Takara LA Taq polymerase and
buffer (Takara Bio Europe/Clontech, 78100 Saint-Germain-
en-Laye, France) was used; for smaller polymerase chain reac-
tion (PCR) reactions, HotStarTaq DNA Polymerase and buffer
system (Qiagen, Crawley, U.K.) was used according to the man-
ufacturer’s instructions. Specific PCR conditions for each primer
set are available on request. PCR products were purified using
QiaQuick PCR spin columns (Qiagen) or ExoSAP (using exonu-
clease 1 and shrimp antartic phosphatase) and sequenced using
internal primers on an ABI 3700 Automated DNA sequencing
machine (Applied Biosystems, Foster City, CA, U.S.A.). Previ-
ously unreported mutations were excluded from at least 90 con-
trol DNA samples (180 chromosomes) by sequencing or
restriction enzyme digests. The occurrence of sequence changes
was also checked on the Exome Variant Server (http://evs.gs.
washington.edu/EVS) and dbSNP database.
RNA extraction
A 3-mm punch biopsy was taken from an affected individual
from family 17 with splice-site mutation K6a c.541–2A>G
and put in RNAlater (Life Technologies, Paisley, U.K.). mRNA
was extracted using a Quick Prep Micro mRNA purification kit
(GE Healthcare UK, Little Chalfont, U.K.) and reverse tran-
scribed using AMV Reverse Transcriptase (Promega, South-
ampton, U.K.). cDNA was amplified using the Expand High
Fidelity PCR system (Roche, Mannheim, Germany) with prim-
ers specific for K6a within exon 1 through exon 5.
Cloning of polymerase chain reaction fragments
The splice-site mutation K6a c.541–2A>G was confirmed by
cloning the PCR product derived from cDNA (above) into
pCR2.1 vector (TA cloning kit; Life Technologies). Several
independent clones were sequenced.
K16 constructs and transfections
Full-length K16 cDNA was cloned into expression vector
pCR3.1 (Life Technologies) and used as a template for site-
© 2014 The Authors. British Journal of Dermatology
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directed mutagenesis (Stratagene, Cedar Creek, TX, U.S.A.) to
make constructs containing K16 p.Arg418Cys and K16
p.Arg418Pro. The three plasmids were transfected individually
into PtK2 cells using Lipofectamine 2000 (Life Technologies),
according to the manufacturer’s protocol. Cells were fixed at 48
and 72 h post-transfection in 1 : 1 methanol : acetone for
5 min, air dried and double-label immunofluorescence was per-
formed. Transfected K16 was detected with rabbit polyclonal
antisera (1 : 500 dilution) against human K16 (gift of Pierre
Coulombe, Johns Hopkins University, Baltimore, MD, U.S.A.)
and the endogenous K8 with neat supernatant monoclonal anti-
body LE41 to PtK2 K8 (gift of Birgitte Lane, Institute of Medical
Biology, Immunos, Singapore). Alexafluor 488 goat anti-mouse
and Alexafluor 594 goat anti-rabbit secondary antibodies (Life
Technologies) were used at a dilution of 1 : 1000. Nuclei were
stained with 40,6-diamidino-2-phenylindole (DAPI).
Results
Clinical details
The main clinical features of individuals involved in this study
are reported in Table 1. All cases were recruited through the
IPCRR, an ongoing research programme to identify patients
with PC worldwide and to collect detailed clinical and molecu-
lar data from all individuals registered. Autosomal dominant
inheritance was observed in 49 of 84 families, while the
remaining cases were apparently due to spontaneous muta-
tions. In many cases with previously reported mutations the
parents were not screened.
Mutation analysis
Of the 84 families, we identified previously unreported het-
erozygous mutations in 14 of them and known heterozygous
mutations in 70 families. The majority were missense muta-
tions, with the remainder being small in-frame deletion,
frameshift, nonsense or splice-site mutations in KRT6A, KRT6B,
KRT6C, KRT16 or KRT17 (Table 1).
Mutations in KRT6A (PC-K6a)
Thirty-one families had mutations in KRT6A and of the 18 dif-
ferent mutations, four, including a nonsense mutation, were
previously unreported. The most commonly reported mutation
in PC is K6a p.Asn172del, found in 10 families here, and
overall in ~30% of kindreds with mutations in K6a and in
~13% of all families with a PC mutation (including published,
www.interfil.org, and those reported here).
A novel missense mutation, K6a p.Phe174Ile, was identified
in family 13; other amino acid substitutions at this residue
have been reported, p.Phe174Ser in at least 12 families,
including one in this study, and p.Phe174Cys in one family.17
Mutation K6a p.Glu473GlyfsTer91 (family 30), an
unreported frameshift mutation at the end of the 2B domain of
K6a, is due to duplication of a single ‘G’ nucleotide,
c.1417dupG. This results in a frameshift starting with codon
473, which is changed from glutamic acid to a glycine residue
and creates a premature stop codon at position 91 of the new
reading frame; this is predicted to cause loss of normal protein
function through protein truncation. Specifically, the last 92 cor-
rect amino acids are replaced by 90 incorrect amino acids, which
are very different in sequence leading to a foreign protein
(Fig. 2). A previously reported mutation, K6a p.Ser505Glnf-
sTer59, downstream of the above mutation, also resulted in a 1-
bp insertion,16 this time in the V2 domain, and the resulting 58
foreign amino acids were the same as in the above mutation.
A previously unreported nonsense mutation, K6a p.Glu461-
Ter (in Family 21) at the start of the helix termination motif
in the 2B domain of K6a, results in a premature stop codon
leading to a truncated protein lacking the helix termination
motif and tail domain. Missense mutations have previously
been reported at this position: K6a p.Glu461, p.Glu461Lys
and p.Glu461Gln (www.interfil.org).
Splice-site mutations were found in six families in KRT6A.
In five of these (families 16–20) mutations were at the intron
1/exon 2 boundary of K6a; three different sequence changes
were identified, all of which we have reported previously,16
but at that time, owing to the unavailability of mRNA, we
were unable to identify the mutations at the protein level.
However, in this study we obtained mRNA from a skin biopsy
from an affected individual from family 17 with mutation K6a
c.541–2A>G. The resulting cDNA was amplified by PCR and
cloned, and several clones were sequenced to identify the con-
sequence of this mutation. The mutation is predicted to result
in an in-frame deletion of the first six amino acids of exon 2,
K6a p. Val181_Gln186del. mRNA was unavailable from other
families with the different sequence changes at this splice site.
In a sixth family (family 31) a previously unreported splice-
site mutation was identified at the exon 8/intron 9 boundary
(c.1460–1G>C); unfortunately, we were unable to obtain
mRNA from this family to determine the effect of this geno-
mic mutation on RNA splicing.
Mutations in KRT6B (PC-K6b)
Mutations in KRT6B were found in nine families, of which one
was novel. Only three different mutations have previously
been reported in KRT6B17 (www.interfil.org): p.Asn172del,
p.Glu461Lys and p.Glu472Lys. Here, eight of the nine families
with mutations in KRT6B had mutations at these sites, further
indicating that these are mutation hotspot residues in KRT6B:
p.Asn172del (families 32–35), p.Glu461Lys (family 36) and
p.Glu472Lys (families 38–40). Family 37 was found to have
an unreported missense mutation within the 2B domain of
KRT6B, p.Leu469Arg. The analogous mutation has been
reported in KRT6A (www.interfil.org).
Mutations in KRT6C (PC-K6c)
Only two families (families 41 and 42) had mutations in
KRT6C, both with the same known mutation, p.Glu472Lys.
© 2014 The Authors. British Journal of Dermatology
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Mutations in KRT16 (PC-K16)
Mutations in KRT16 were found in 24 families; the most com-
mon recurrent mutations identified were K16 p.Asn125Ser,
p.Arg127Cys and p.Leu132Pro (www.interfil.org). Five of the
14 distinct K16 mutations were previously unreported. The
20 or more different mutations reported in keratin 16 include
p.Arg127Cys and p.Arg127Pro. In this cohort, we identified
previously unreported mutations in three families (families
55, 61 and 62) at K16 p.Arg127: p.Arg127Gly, p.Arg127Ser
and p.Arg127His. We also identified one additional family
(family 54) with mutation p.Arg127Pro and five families
(families 56–60) with p.Arg127Cys. Interestingly, the pheno-
typic variation seen with these latter two mutations indicates a
genotype–phenotype correlation, as proposed in a small
study.18 Fu et al. showed that individuals with mutation
p.Arg127Cys were more likely to have milder features of the
disorder (milder nail changes, less palmoplantar pain, etc.)
than those with amino acid substitution p.Arg127Pro.18
Including these additional mutations, ~24% of reported muta-
tions in KRT16 occur at this p.Arg127 (www.interfil.org).
Interestingly, a proline substitution for arginine was found
to be deleterious in another portion of the helix, whereas a
cysteine substitution was not. In Family 65, we identified a
new mutation K16 p.Arg418Pro. This mutation in the helix
termination motif domain of K16 is predicted to be patho-
genic. The unaffected parents of the proband were both wild
type. Another sequence change at this position, p.Arg418Cys,
which might be predicted to be pathogenic owing to its posi-
tion within the helix termination motif, is listed on the dbSNP
database (minor allele frequency from 1000 Genomes project
= 19%) and also on the Exome Variant Server (http://evs.gs.
washington.edu/EVS/), indicating that it may be a nonpatho-
genic sequence change. We also found p.Arg418Cys in one of
92 anonymous unrelated control DNA samples and in some
members of three unrelated PC families in which known
mutations were identified in KRT6A, KRT16 or KRT17. To inves-
tigate the effect of these sequence changes at K16 p.Arg418,
PtK2 cells were transfected with plasmids expressing either
wild-type K16, K16 p.Arg418Cys or K16 p.Arg418Pro cDNAs.
At 48 h and 72 h post-transfection cells were fixed, and
stained with a polyclonal antibody against K16 to detect trans-
fected K16. Endogenous K8 was detected with monoclonal
antibody LE41 to PtK2 K8. Nuclei were stained with DAPI.
Cells were examined for those containing filaments, filaments
plus aggregates or only aggregates. In cells transfected with
wild-type K16, 895% of transfected cells showed a defined
keratin cytoskeleton where wild-type K16 co-localized with
endogenous K8; the remaining 105% of transfected cells had
filaments plus aggregates. Cells transfected with K16
p.Arg418Cys showed a similar pattern to wild-type K16, with
89% of transfected cells with normal filament network and
11% of cells with filaments plus aggregates. However, in cells
transfected with K16 p.Arg418Pro, 985% of cells contained
aggregates and there was collapse/aggregation of the endoge-
nous network; only 15% of transfected cells showed a normalTa
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filament network (Fig. S1). These results demonstrate that the
mutation p.Arg418Pro is disruptive to the normal filament
network formation, which, in vivo, would result in PC, whereas
p.Arg418Cys, in vitro, produces a normal filament network
similar to wild-type K16 and is therefore unlikely to be patho-
genic.
Another novel mutation identified in K16 is a 6-bp in-
frame deletion mutation, K16 p.Arg418_Arg419del, in family
66, which results in the deletion of two amino acids from the
helix termination motif.
Mutations in KRT17 (PC-K17)
KRT17 mutations were found in 18 families and included four
novel mutations. The most common known mutation found
was K17 p.Asn92Ser; including previous publications (www.
interfil.org) and this study, it occurs in ~8% of PC families
with a confirmed mutation.
Three previously unreported missense mutations were iden-
tified in KRT17. Family 78 was found to harbour a mutation
in K17, p.Arg94Ser. p.Arg94 is a residue already known to be
susceptible to mutation owing to several reported cases result-
ing in amino acid substitutions p.Arg94Cys, p.Arg94His and
p.Arg94Pro (www.interfil.org). Two other unreported muta-
tions in K17 were p.Met88Arg (family 68) (mutations have
been previously found at this residue p.M88, p.Met88Lys and
p.Met88Thr) and p.Leu91Pro (family 70). A novel insertion/
deletion mutation in K17, p.Asn90_Asp93delinsIle, found in
Family 69, results in deletion of 10 nucleotides and insertion
of one nucleotide (T). This leads to an in-frame deletion in a
critical region within the helix initiation motif.
Discussion
The mutations identified in these 84 families add to the increas-
ing data set of the IPCRR of detailed clinical information and
corresponding molecular data of individuals with PC. In all
cases, the mutations were heterozygous sequence changes –
missense, nonsense, small deletion/insertion or splice-site
mutations – confirming this is predominantly, if not exclusively,
an autosomal dominant disorder. While there are a few case
reports of recessive PC reported in the literature,19 as yet there
are no recessive cases with confirmed genetic testing.
The majority of the mutations identified have been previously
reported with some mutations, for example K6a p.Asn172del,
K16 p.Asn125Ser, K16 p.Arg127Cys and K17 p.Asn92Ser occur-
ring frequently. For development of mutation-specific forms of
treatment, for example small interfering RNA, these residues
that are commonly mutated would be obvious targets owing to
the larger number of patients that could potentially be treated.
(a)
(b)
Fig 2. Kyle–Doolittle hydrophilicity analysis of normal and mutant K6a. (a) Normal K6a tail domain consists of alternating hydrophobic and
hydrophilic sequences compared with (b) the mutant tail domain, K6a p.Glu473GlyfsTer91, which is mainly hydrophilic.
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More than a third of cases analysed in this study had mutations
in K6a, which may partly be reflected by the fact that individuals
with K6a mutations tend to present with the most severe fea-
tures of PC and are therefore more likely to search/ask for sup-
port, find the PC Project website (www.pachyonychia.org) and
join the IPCRR. Conversely, only two families were identified
with mutations in KRT6C. In family 42, the proband had for
many years been diagnosed with EBS due to blistering of palms
and soles and subsequent hyperkeratosis. From the four cases
previously reported with KRT6C mutations,17 together with
those in this report, it appears that these individuals present
with a milder clinical phenotype than those with mutations in
KRT6A, KRT6B, KRT16 or KRT17. Information regarding the phe-
notype of those with mutations in KRT6C is limited due to the
small number of reported cases but this could be explained as
only rarely do they come to clinical attention.
The results reported here, together with previously pub-
lished data, are summarized in Figure 3, which shows the
spectrum of mutations in the five keratin genes associated
with PC: KRT6A, KRT6B, KRT6C, KRT16 and KRT17.
The overlapping phenotype of inherited PPKs, independent
of their genotype, can make diagnosing them clinically a con-
fusing field.
Individuals presenting with symptoms of PC should
undergo genetic analysis for mutations in the five known PC
genes (KRT6A, KRT6B and KRT6C, KRT16 and KRT17). In addi-
tion, other candidate genes may need to be considered,
including GJB6 encoding connexin 30,20 desmoglein 1
(DSG1),21 desmoplakin (DSP),22 keratin 9 (KRT9),17 and friz-
zled 6,23,24 mutations in that mimic some features of the PC
phenotype and hence should be encompassed into the
differential diagnosis of PC. For example, individuals with
mutations in connexin, 30 present with nail dystrophy, some
PPK and alopecia. The severity of the alopecia varies widely
from very subtle to total alopecia but is a key indicator of
Clouston syndrome due to mutations in connexin 30, rather
than a diagnosis of PC. Autosomal dominant mutations in
DSG121 and DSP, typically result in striate PPK,25 although this
can also occur in some patients with PC.
Autosomal recessive cases due to desmoplakin mutations
also have features that overlap with PC, including palmoplan-
tar blistering and keratoderma with nail dystrophy, which can
lead to misdiagnosis. However, these individuals also have dis-
tinctive sparse, woolly hair and, importantly, they are at risk
of cardiomyopathy. Therefore, diagnosis at the molecular level
is important for these individuals in defining the risk of car-
diomyopathy and to allow appropriate monitoring of their
condition.
Mutations in FZD6 were recently discovered as the cause of
autosomal recessive nail dysplasia.23 These individuals present
with 20-nail dystrophy from birth or shortly afterwards in the
form of thickened, discoloured, claw-shaped nails. There is no
involvement of other ectodermal tissues. FZD6 screening
should be considered for any spontaneous cases or known
recessive cases with isolated nail dystrophy.
Genetic analysis of the cases in this study has confirmed
their clinical diagnosis of PC. A small number of cases within
the IPCRR (not reported here) that are clinically not typical of
PC have been shown to have mutations in the other genes
mentioned above. Correct molecular diagnosis is important to
aid in appropriate genetic counselling and patient care. This
large, well-phenotyped and genotyped case series is an invalu-
able resource for the development of mutation-specific and/or
gene-specific therapies, and for future clinical trials.
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Supporting Information
Additional Supporting Information may be found in the online
version of this article at the publisher’s website:
Figure S1. Double-label immunofluorescence staining of
cells transiently transfected with K16 wild-type and mutant
K16. (a) K16 wild-type, (b) K16 p.Arg418Cys and (c) K16
p.Arg418Pro cDNAs in epithelial cell line PtK2. K16 was
detected with rabbit polyclonal antisera against human K16
and the endogenous K8 with monoclonal antibody LE41 to
PtK2 K8. Nuclei were stained with 40,6-diamidino-2-phenylin-
dole (DAPI). In cells transfected with wild-type K16, 895% of
transfected cells showed a defined keratin cytoskeleton where
wild-type K16 co-localized with endogenous K8; the remain-
ing 105% of transfected cells had filaments plus aggregates. In
cells transfected with K16 p.Arg418Cys, similar to wild-type
K16, 89% of transfected cells had a normal filament network
and 11% of cells had filaments plus aggregates. In contrast, in
cells transfected with K16 p.Arg418Pro, 985% of cells con-
tained aggregates and there was collapse/aggregation of the
endogenous network; only 15% of transfected cells showed a
normal filament network. Original magnification 9 60.
Table S1. Polymerase chain reaction primers for specific
amplification of pachyonychia congenita-associated keratin
genes.
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